Company news
Capricor Therapeutics, Inc. news in 2021
Capricor Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
December 12, 2021
Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 8, 2021
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
September 23, 2021
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
September 1, 2021
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 11, 2021
Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
August 3, 2021
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
July 26, 2021
Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
April 28, 2021
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 10, 2021
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
March 8, 2021
Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
March 3, 2021
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
January 31, 2021
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
January 18, 2021
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
January 11, 2021
Calls in 2021
- Capricor Therapeutics (NASDAQ:CAPR) Q3 2021 Earnings Call
Nov 9, 2021
Transcript - Capricor Therapeutics (NASDAQ:CAPR) Q2 2021 Earnings Call
Aug 12, 2021
Transcript - Capricor Therapeutics (NASDAQ:CAPR) Q1 2021 Earnings Call
May 13, 2021
Transcript - Capricor Therapeutics (NASDAQ:CAPR) Q4 2020 Earnings Call
Mar 11, 2021
Transcript
Decks in 2021
- Technical Presentation (September 2021)
Technical · 25 slides · Sep 24, 2021
- Q4 2020 Earnings Presentation
Earnings · 18 slides · Mar 11, 2021